ACCOMPLISHMENTS

We are on a mission to halt the progression of Alzheimer's Disease and we are moving with enthusiasm and passion to attain that objective. We have made enormous strides toward our goal. Some of our most recent accomplishments include:

• In December 2004, we opened the Voyager Research Labs in Research Triangle Park, NC.  Our internal labs will focus on further exploring our basic scientific hypothesis in a number of specific therapeutic targets.  Our initial areas of focus will be Amyotrophic Lateral Sclerosis (Lou Gherig's Disease), Hormone Refractory Prostate Cancer, Brain Cancer, improving fetal development in pre-term infants, Parkinson's Disease, Childhood Leukemias.


• We continue to add outstanding talent to our team that is guiding us through all required development processes. These resources include internal and external experts in basic scientific research, drug development, manufacturing, clinical research and regulatory affairs.


• In February 2003, we successfully initiated our double blind, placebo controlled, one year Phase II clinical trial in women to demonstrate the efficacy and safety of our patented product in the treatment of Alzheimer's Disease.


• In December 2003, we successfully completed enrollment in this  Phase II trial in women only.


• In March 2004, we initiated our open label extension study for women who complete our one-year, double blind, placebo controlled Phase II trial.


• In December 2003, we initiated a one-year, double blind, placebo controlled Phase II clinical trial in men, designed to further demonstrate the efficacy and safety of our patented product in the treatment of Alzheimer's Disease.


• We are continuing to build relationships and collaborate on additional research with a network of leading Alzheimer's researchers across the United States and in Australia. These efforts continue to generate important new data that supports our hypothesis and offers a strong scientific case for use of our patented treatment.


• We have published our findings in a number of respected, peer-reviewed journals. Most recently, we reported in the The Journal of Biological Chemistry, a link between the marked increases in serum LH following menopause/andropause and Aß secretion and deposition in the aging brain. (Click here to view our latest articles)


• Working with DURECT Corporation, a leading drug development company, we have completed initial development of our unique dose and delivery formulation for our patented Alzheimer's treatment.


• In collaboration with recognized epidemiologists, we recently completed an epidemiological study that offers compelling data and findings, that further support the hypothesis and provides additional evidence of the potential efficacy of our patented Alzheimer's treatment.


• We have broadened our research platform beyond Alzheimer's Disease, by filing for patents covering proprietary treatments for numerous diseases including Parkinson's, atherosclerosis, brain cancer, osteoarthritis, osteoporosis and colon cancer.


• We initiated toxicology studies in December 2003 on our unique dose and delivery formulation of our patented treatment.